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The article by Johns et al. (1) compares the Hopkins Symptom 
Checklist 20-item depression scale (HSCL-20) (2), the 
Short-Form 36 Mental Health Inventory five-item distress 
scale (MHI-5) (3), and the Patient Health Questionnaire 
nine-item depression scale (PHQ-9) (4) in 309 adults 
with cancer in a longitudinal study. The authors compare 
internal consistencies and construct validity. Moreover, they 
address responsiveness of these three scales to results of a 
systematic treatment of depression over three-months by 
comparing these measures to patients’ self-reports of their 
depressive symptoms (improved, no change, or worsening). 
These comparisons provide clinically relevant information 
considering the fact that studies find comorbidity of cancer 
with depression ranging from 3-77% with especially 
high numbers in patients receiving palliative care (for 
a review see) (5). As Vodermaier et al. (6) point out, the 
wide range of prevalence rates can be partially explained 
by differences in diagnostic criteria and instruments 
used to measure depression. Taking this into account 
and considering the significant negative consequences 
of depression (including but not limited to functional 
impairment, reduced quality of life, poor treatment 
adherence, and even increased mortality; for reviews see) 
(6-8), Johns et al.’s (1) focus on patient-reports of depression 
with good psychometrics address an important topic.
Johns et al. (1) report good internal consistencies and 
construct validity at baseline for all three scales. Looking 
into responsiveness, John et al. (1) confirm that all three 
instruments differentiate between patients reporting their 
depression as improved, unchanged, or worse after three 
months of systematic treatment and each of these measures 
is able to depict a treatment effect when compared to a 
control group. Finally, using receiver operating curve 
analysis the scales distinguish improved from non-improved 
patients. In summarizing, this study is indicating the HSCL-
20 (2), the MHI-5 (3), and the PHQ-9 (4) to be appropriate 
measures to assess depressive symptoms in adult cancer 
patients based on their psychometric values. From a clinical 
point of view, this is an encouraging result, as all three 
measures are short and therefore easily utilized in a patient 
population oftentimes challenged by limited attention span 
and fatigue (9). Moreover, the straightforward scoring 
options for each of the scales increase the likelihood of their 
application in busy clinical settings. 
One other interesting finding that Johns et al. (1) report 
is that two abbreviated versions of the studied instruments 
(MHI-d and PHQ-2) show less responsiveness to changes 
in depression when compared to the full length instruments 
(HSCL-20, MHI-5, PHQ-9). Johns et al. (1) use this pattern 
of findings to engage in the debate whether depression 
instruments that contain somatic items overestimate the 
associations between depression and cancer [e.g., (7,10-14)]. 
This discussion is fueled by the fact that the DSM-IV 
relies heavily on somatic symptoms for the diagnosis of a 
depressive disorder and these symptoms are seen commonly 
in cancer patients as result of their illness progression or 
as adverse effects of their treatments (e.g., fatigue, poor 
appetite, sleep problems). Therefore, the interpretation 
of somatic symptoms has been labeled as one of the 
most common problems in diagnosing depression in 
cancer patients (15). However, Johns et al. (1) argue their 
findings that instruments including somatic items show 
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more responsiveness to demonstrate that somatic items 
do not lead to an overestimation of depression in cancer 
patients. Nevertheless, such interpretations need to be 
made cautiously as change in depression is only assessed by 
patient-responses to the retrospective question, ‘‘Overall, 
since starting the study, would you say that your depression 
is worse, about the same, or better?’’. It might be that 
patients include their overall well-being and physical 
symptoms into their own depression evaluation as they are 
not given any criteria on how to assess their depression. 
This may be particularly true as patients have been asked 
this question after repeatedly filling in the questionnaires 
(including somatic symptoms) that might shape their 
impression of how the researchers define depression. 
Therefore, the patient report may at least in part be based 
on symptoms related to the patient’s cancer or treatment 
side effects rather than their depression. In line with this 
topic, a recent meta-analysis about depression as predictor 
of the development of breast cancer found that studies 
using depression instruments including somatic items 
found stronger associations between cancer and depression 
than studies that do not assess these symptoms (16). This 
underscores the need for future research to clarify this issue 
further.
In conclusion, Johns et al.’s (1) study is set apart from 
other attempts to evaluate depression scales by taking the 
extra effort to utilize a longitudinal design. Moreover, 
including three measures in their research design allows 
for comprehensive discussions. Given these advantages, 
it would have been desirable to include instruments with 
widespread clinical utilization like the Hospital Anxiety 
and Depression Scale (HADS) (17), even if they have been 
researched in cross-sectional designs before. Considering 
that the HADS is one of the most often utilized instruments 
to measure depression in cancer patients (8) and the fact 
that recent reviews of depression instruments come to the 
conclusion that the HADS is one of the best instrument for 
assessing depression in cancer patients (6-8), the inclusion of 
the HADS would allow to compare the findings regarding 
the HSCL, MHI, and PHQ to this “gold standard” of 
patient-reports in cancer patients.
Depression is one of the most common mental health 
problems in palliative care (18) but current literature 
still reports concerning underdiagnosing of depressive 
disorders in this patient population (19,20). Efforts 
to provide psychometrically sound tools to assess for 
depressive symptoms are one important step to address this 
challenge. As many settings still do not have mental health 
professionals readily available to routinely assess all cancer 
patients (9), future research is needed to focus on how 
these assessment tools can be used by other professionals 
(e.g., nurses) to screen for emotional distress in general 
and depressive symptoms in particular to trigger referrals 
to specialized professionals who are qualified to diagnose 
depressive disorders.
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